SEC Form 4 · accession 0001209191-17-058849
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eilon D. Kirson
Officer — Chief Science Officer
Period of report
Oct 31, 2017
Accepted (ET)
Nov 2, 2017 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Oct 31, 2017 | S | 150 | $22.00 | D | 63,120 | D | |
| Ordinary SharesF2 | Nov 1, 2017 | S | 22,119 | $22.0087 | D | 41,001 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson.
- F2On November 1, 2017, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Kirson, Mr. Kirson sold 22,119 shares in multiple trades at prices ranging from $22.00 to $22.10. The price reported above reflects the weighted average sale price. Mr. Kirson hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected.